by Dennis Crouch
Although Nautilus made it easier for a court to find claim terms indefinite, the Federal Circuit continues indicate that the definiteness test strongly favors validity.
In Niazi Licensing Corp. v. St. Jude Medical S.C., Inc. (Fed. Cir. 2022), the court has sided with the patentee–rejecting the district court’s indefiniteness finding.
Niazi’s US6638268 covers a double lined catheter designed for placing an electrical lead in the coronary sinus vein. The outer catheter is a “resilient catheter having shape memory and a hook shaped distal end.” The inner catheter is a “pliable catheter.” In Figure 8 below, you can see that the larger outer catheter can get most of the way to the vein destination, but its less-pliable construction makes it difficult to follow all the twists. The pliable inner catheter is then inserted and extended to reach the vein location.
D.Minn. Judge Wright found the terms “resilient” and “pliable” indefinite and therefore that the claims were invalid. On appeal, the Federal Circuit has reversed–holding that terms meet the requirement of “reasonable certainty.” Nautilus, Inc. v. Biosig Instruments, Inc., 572 U.S. 898 (2014).
Patent law’s definiteness requirement is derived from the requirement that patent claims “particularly pointing out and distinctly claiming the subject matter” of the invention. 35 U.S.C. 112. The purpose of express claims is to provide public notice of the scope of exclusive rights so that competitors and potential copycats can arrange their affairs to avoid infringement. (We could pause here to question whether competitors and potential copycats do this in the ordinary course or if it is instead merely legal fiction.) But, the Supreme Court has also recognized that claims need not perfectly delineate claim scope — rather, the claims must provide “reasonable certainty” as to their scope. Nautilus. In particular, the Federal Circuit has repeatedly found terms of relative degree to be definite so long as POSITA would have “enough certainty.” Further, “a claim is not indefinite just because it is broad.” Slip Op. On the other hand, “purely subjective” claim terms are indefinite — such as “aesthetically pleasing” as used in Datamize, LLC v. Plumtree Software, Inc., 417 F.3d 1342, 1345, 1349–56 (Fed. Cir. 2005) (there must be some “objective anchor”).
Here, according to the court, Niazi’s claims terms provide enough guidance to avoid being labelled indefinite.
- Resilient: The claims require “an outer, resilient catheter having shape memory.” In its decision, the court concluded that resilient is guided by the “shape memory” requirement. The specification further explains that it may have a “braided design.” and may be made of “silastic or similar material” with the purpose of “return[ing] to its original shape” after being distorted. The specification also categories resilience in terms of both torque control and stiffness.
- Pliable: The claims require “an inner, pliable catheter slidably disposed in the outer catheter.” The specification provides further explanation: “constructed
of a more pliable, soft material such as silicone;” and without “longitudinal braiding, which makes it extremely flexible and able to conform to various shapes.”
In addition to each having some amount of support from the specification, the court also noted that the two terms can be read relative to one another– the pliable inner catheter must be “more flexible than the outer.”
Definiteness is ordinarily a question of law and so the Federal Circuit reviews the issue de novo on appeal. Here, the court found sufficient reasons to find the terms definite. Reversed.
Note: The court also considered dictionary definitions. It did not discuss whether those definitions introduced extrinsic evidence requiring deference rather than de novo review.
= = = =
Niazi’s Claim 11 is a method-of-use claim that did not use the pliable/resilient terms. Thus, it survived the district court indefiniteness attack. The defendant here St. Jude supplied the accused catheter, and Niazi argued that St. Jude had induced doctors and hospitals to infringe. The district court found no inducement. On appeal, the Federal Circuit affirmed — holding that under the correct construction of the claim terms there was no underlying direct infringement.
= = = =
Exclusion as a Discovery Sanction: In his expert report, Dr. Niazi’s technical expert (Dr. Burke) stated that he had personally infringed the Niazi patent while using the accused products. The problem: Dr. Burke had not been identified as a fact witness as required by R.26(a)/(e). Dr. Niazi’s damages expert relied upon several license agreements to support his report. However, those agreements were not identified during fact discovery despite a specific request for documents. Both expert reports were provided after the close of fact discovery (as is common). As a sanction for the late disclosures, the District Court struck those facts from the expert reports and barred Dr. Burke from testifying as a factual witness. On appeal, the Federal Circuit affirmed on a technical ground — finding that Niazi’s appeal on this question failed because he did not challenge the actual basis for the district court’s decision–whether the delay in disclosure was “substantially justified or harmless.”
Despite the exclusion order, Niazi still presented a declaration from Dr. Burke in support of summary judgment that included a number of factual claims based upon Burke’s personal experience. The district court struck the statements and also awarded monetary sanctions under R. 37. The Federal Circuit affirmed:
Here, the sanctions the court imposed were specifically keyed to St. Jude’s expenses in moving to strike the already-excluded evidence from consideration at summary judgment. We see no abuse of discretion in the district court’s decision to award monetary sanctions.
Slip Op.
= = = =
Finally, the district court also excluded Niazi’s damage expert report as unreliable.
The district court excluded Mr. Carlson’s expert opinion as legally insufficient because Mr. Carlson failed to “apportion” between infringing and noninfringing uses and because he could not properly include leads in the royalty base. We affirm the district court’s exclusion.
Slip Op. Here, the idea was that St.Jude agued that some uses were non-infringing and the expert did not attempt to apportion-out the non-infringing uses but instead merely stated that apportionment would be “impractical in view of real-world considerations.”
Here, the claim was that sales by St. Jude (along with its instructions) were inducing infringement the method-of-use claims. The patentee argued that apportionment does not apply to method claims. But, the Federal Circuit disagreed with that broad statement. “Damages should be apportioned to separate out noninfringing uses, and patentees cannot recover damages based on sales of products with the mere capability to practice the claimed method. Rather, where the only asserted claim is a method claim, the damages base should be limited to products that were actually used to perform the claimed method.”
Looking in from Europe, several thoughts occur, on the issue of indefiniteness. First, I agree with Judge Stoll, that the idea behind the requirement to be definite is that the public needs to know what infringes the claim (and what does not). A degree of “fuzziness at the edge of the claim” (as the English courts have it) is inevitable, given the fact that all we have to define the borders of the claimed territory is mere words, but more than that degree is unacceptable.
But here, with resilient and pliable, there is no fuzziness at all because the outer catheter cannot be anything else but “pliable” and the inner nothing else but resilient. Otherwise, the device cannot function and will be liable to injure the vasculature into which it is advanced.
The corollary is of course that the terms pliable/resilient are barely limiting. All they do is to limit the claim to devices that work. But, in practice, limiting a claim to that which works is an essential skill in writing good quality claims. Here, I think the inclusion of resilient and pliable is good drafting which ought not to be brought down by a spurious indefiniteness objection.
That said though, any term of degree in a claim is prima facie indefinite.
Ah, now I see. I just wrote that the tubular catheter is the pliable element and the inner wire the resilient element. Silly me: it seems that it is the outer catheter element that must be “resilient” and the inner element the one that has to be “pliable”. How could I have got that wrong?
The way I see it, both of the co-axial catheter elements have to be both resilient and flexible. I mean, the catheter is about 4 ft long. You introduce it at the thigh and push it through the tortuous vasculature, all the way to the heart. Think pushability/torquability and compare the catheter first with i) an uncooked strand of spaghetti and then with ii) a well-boiled strand of spaghetti.
I have no idea whuch is more i) pliable or ii) resilien, the material of the outer tube or the inner wire. Not that it matters though. What counts is the flexibility, pushability and torquability of each of the two catheter elements, individually and collectively. It was ever thus, in this decades old and by now very mature field of endeavour.
I do hope that the patent owners wasn’t relying on pliable/resilient for patentability over the art. That would be ridiculous, wouldn’t it?
The self-imposed irony….
link to patentlyo.com
No, wait….
“That said though, any term of degree in a claim is prima facie indefinite.”
Please shut the F up.
Iancu was sworn in 3 days after confirmation. Vidal will be sworn in 9 days after confirmation.
Indicator she’s not in a rush to do much?
She’s not in a rush…? Based on a schedule set by others…?
Apr 14?
No, the 13th. I miscounted.
No mention of a nose of wax in the decision?
“Damages should be apportioned to separate out noninfringing uses, and patentees cannot recover damages based on sales of products with the mere capability to practice the claimed method. Rather, where the only asserted claim is a method claim, the damages base should be limited to products that were actually used to perform the claimed method.”
How should the above comment by the court be applied to skinny labeling in pharma method of treatment cases? Unfortunately, if a drug is indicated for multiple uses, we are not sent to the pharmacy to get drug X for indication Y. Rather, your Dr. just writes a script for drug X. Is there a practical way to parse out damages based on use with respect to approved generics with skinny labeling? If one cannot parse out non-infringing uses, what metric should a could use to apportion damages?
Most of the indefiniteness rejections I get seem to come from new(er) Examiners. Many Primaries don’t even seem to want to waste time on 112 rejections unless there is something truly blatantly wrong. Even with the new(er) Examiners, most indefinite rejections seem to spring from them not having read the specification.
I’ve seen the same thing. I would note that I see this primary for 112(b) indefiniteness, not 112(a) written description or enablement.
I guess I’m one of those primaries who have time to waste – I issue indefiniteness rejections all the time. But then, I’m what you would likely call a new(er) primary [10 years].
I’ve always felt that the old timer primaries [i.e., 25+ years] don’t issue indefiniteness rejections because they haven’t bothered to update themselves. Most of them were trained way-back-when when the law of the land at the fedcir on indefiniteness only required just one reasonable interpretation, so the old timers would just let the claim go if they can find one reasonable way to understand it. But, (i) this federal circuit indefiniteness rule was overturned later by NAUTILUS and (ii) that fedcir rule was only ever applicable to post-issuance claims where the validity presumption had attached, not claims under examination. Unfortunately, the old timers are still passing down their wisdom to the juniors.
Interesting and seems like a likely explanation for some of the goings-on.
“the Federal Circuit continues indicate that the definiteness test strongly favors validity.”
As should SCOTUS’ judicially-created, smoke-and-mirrors, Congress-usurping Mayo / Alice test.
CAFC, what say you?
Are adjectives “functional?”
They certainly are not “structural” (objective or otherwise).
Where are all of our Examiner Experts?
Or is it only the computing arts that raise their ire?
Comments are closed.